The year 2000 is poised to be declared the 'Year of the Genome'. The sequences of human chromosomes 21 and 22 have been published in the past six months, and two further landmark announcements are expected within days -indeed, may even have been made by the time you read this. Scientists of the Human Genome Project are on the verge of announcing completion of a "rough draft" of the human genome. And the world should soon hear another stunning proclamation from Celera Genomics, which recently completed a genome draft and is now assembling its data into near-final form.
But amid all the bluster about who will deliver the sequence first, there's been little attention paid to the quality and completeness of the data we'll have after the sensational announcements are made and the hoopla's died down. What, for instance, is meant by a 'rough draft'? The rough draft from the Human Genome Project -an international consortium of labs funded primarily by the US government and the UK's Wellcome Trust -will sequence 90% of the roughly 3.2 billion bases of the human genome. Celera says its soon-to-be-finished product (for which it is also using the public-domain data) will be 99% complete. The criteria for completion of these stages are arbitrary. Finishing the job will be the hardest part, a matter of diminishing returns, and 1-3 years may be needed to tackle those remaining percentage points by closing the thousands of gaps in the sequence.
Which raises the question: Are the not-quite-finished data we're about to see reliable, and useful for biomedical research? Or are the numerous gaps in the sequence a tiny problem with huge effects?
In answering these questions, it's important to know why the gaps exist at all. There are two types of gap: one is a statistical artifact, the other is biologically meaningful. Statistical gaps are a byproduct of the 'shotgunning' sequencing methods used by both the public and private efforts. DNA is chopped up into small pieces randomly, and the pieces are sequenced enough times to cover any particular point on the genome several times over, on average. Computer programs then search for overlap among the sequences and connect and order the fragments into a linear whole. By chance, some stretches will be covered many times over, whereas others will be missed completely; the more sequencing, the fewer gaps will remain.
What exactly is meant by a 'rough draft' of the human genome?
The second type of gap occurs when a stretch of DNA refuses to cooperate with the sequencing techniques. It may be incompatible with the bacterial cloning agent and not get cloned. It may throw off the sequencing enzymes because of a highly biased composition of bases. Or it may consist of multiple repeated segments, which can be difficult to sequence and can confuse computer programs trying to piece together the fragments.
Statistical gaps are closed during the 'finishing process' simply by doing more shotgun sequencing -but in a directed manner, aiming efforts at regions in which gaps occur. The bits of DNA that are resistant to sequencing are more troublesome, and require creative thinking as technicians test various conditions to try to coax out the recalcitrant DNA. "We won't give up until a number of things have been tried, and we will try hard," says Richard Myers, director of Stanford University's Human Genome Sequencing Center.
But Myers and others concede that some stretches of DNA may never be sequenced, and at some point the heads of labs with the painstaking, less glamorous task of 'finishing' may need to bow to the diminishing returns curve. The public consortium's criterion for finishing is to obtain sequence that's 99.99% complete and accurate. The 'finished' sequence of human chromosome 22 published last December contained only 11 gaps, and that of chromosome 21 published last month had only 10, and was judged 99.7% complete.
But do the gaps matter? Most researchers now desiring genomic data want to use it to recognize particular genes of interest, and for this, the public-domain 90% rough-draft data (and certainly any more-complete data from Celera) should work quite well. A jigsaw puzzle missing a few pieces still gives us most of the picture, and incomplete sequence data do give labs a jump on researching genes and developing applications. In fact, for several years researchers have been using human genome data now being added daily to the GenBank repository. The Human Genome Project sequencers say this is precisely the reason they decided to make unpublished sequence available via GenBank. But for other purposes, a gap-ridden data set might not be good enough. Because regulatory regions may be physically distant from transcribed regions of genes, their likelihood of being separated by a gap is greater. So researchers interested in gene regulation may want to wait for the final product. The same goes for those studying gene clusters, exploring non-coding regions, or comparing sequence divergence across species. For some studies of regulation, however, comparative data from the expected rapid sequencing of other organisms could help compensate for a lack of complete human data, points out Jane Rogers, human sequencing and mapping project manager for the Sanger Centre in Cambridge, UK.
Most gaps may be irrelevant to researchers interested in gene function, as many -in particular, repetitive sequences -are thought to comprise non-coding and/or non-functional regions. The genomic sequence of the fruit fly, published in March, suggests this could be the case; although the sequence contained gaps, virtually all of the 2,783 genes previously described in this model organism were found in the sequence.
Indeed, some say filling in gaps should be the least of our concerns. More important than filling a gap is 'capturing' a gap -determining the order and orientation of sequence on either side of it, so the gap can be located and its size determined, according to Elbert Branscomb, who directs the Joint Genome Institute of the University of California's Lawrence Livermore National Laboratory. As a stubborn gap will probably be non-coding, it might not be important to determine its exact sequence. The fact that most of the public data are not yet ordered and oriented poses limitations on their immediate use, so the first stage in the Human Genome Project's finishing process may need to be ordering and orienting the countless stretches of DNA residing in GenBank. Celera's whole-genome shotgunning approach and subsequent one-fell-swoop assembly, and its use of public-domain data, should produce ordered and oriented sequence.
Both efforts say they are committed to the nitty-gritty work of the finishing process. Although some observers expect Celera's commercial interests may lead it to quit early and move on, the public team seems resolute about finishing. Too much so, in the eyes of some. The public effort, Branscomb says, is trying "to soldier on and beat every last gap out of existence… It's a matter of taste and judgement just how far down that Puritan road you want to go."
Shall we soldier on and beat every last gap out of existence?
David Lipman, director of the National Center for Biotechnology Information, echoes such concerns. "This notion of being 'totally complete' to me is problematical and not that meaningful," he says. "My view of completion is more one based on utility." Others agree, arguing that gap closure should be selective, prioritizing regions of greatest functional interest.
As for Celera, chief scientist Eugene Myers says it won't abandon the human genome "until we're satisfied we have a version of substantial utility." The concept of being 'finished', he stresses, is different for a complex eukaryote whose entire genome may not be accessible with current methods than for a prokaryote whose simpler genome is.
In the meantime, both public and private efforts are already leaping to the next steps -ordering and orienting sequence; identifying and ascribing functions to genes; and sequencing variations on the human theme, cataloging the single-base differences that sometimes may help determine an individual's predisposition for disease. In addition, many labs are actively sequencing the genomes of other organisms for comparative purposes -most immediately, the mouse.
Even if the two sides were to fill all the gaps and proclaim 100% completion, however, that still would not mean every base in the human genome had been sequenced. Sequencing techniques to date are well able to sample DNA only from the 'euchromatic' portion of the genome, and not from the largely repetitive and non-coding 'heterochromatic' region. This is not much of a loss to those interested in finding genes and in questions of functionality -except that growing evidence indicates that heterochromatic regions do contain some genes, although they contain fewer of them and express them at lower levels. "Skipping heterochromatin altogether is not a good thing," says Richard Wilson, co-director of the Human Genome Sequencing Center at Washington University, St Louis.
Regardless, the data being presented by Celera and by the Human Genome Project this year are rightly recognized as a highly useful achievement, even in their not-quite-complete state. The much-trumpeted antagonism between the public and private efforts is now being downplayed by both sides as they recognize their approaches as complementary and somewhat mutually beneficial -and as researchers become excited over seeing light at the end of the tunnel.
Of course, obtaining a full human genome sequence is just the first step in a long and complex process. "It's a little bit like a new continent, the human genome, being explored by the Dutch East India Company on one hand and the US Geological Survey on the other," says Harold Varmus, former head of the National Institutes of Health. "They're each measuring the coast line. Some parts are fogged in; they can't see them." But what will matter in the long run, Varmus says, is "the map that's produced and then, most important of all, what the miners do when they get there -who gets the interesting information out of the continent."
